Literature DB >> 27807282

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.

Jens G Lohr1,2,3, Sora Kim4, Joshua Gould4, Birgit Knoechel4,2,3, Yotam Drier4,3,5, Matthew J Cotton4,5,6, Daniel Gray4, Nicole Birrer5, Bang Wong4, Gavin Ha4,2, Cheng-Zhong Zhang4,2, Guangwu Guo4,2,3, Matthew Meyerson4,2,3, Andrew J Yee3,5, Jesse S Boehm4, Noopur Raje3,5, Todd R Golub1,2,3,6.   

Abstract

Multiple myeloma (MM) remains an incurable disease, with a treatment-refractory state eventually developing in all patients. Constant clonal evolution and genetic heterogeneity of MM are a likely explanation for the emergence of drug-resistant disease. Monitoring of MM genomic evolution on therapy by serial bone marrow biopsy is unfortunately impractical because it involves an invasive and painful procedure. We describe how noninvasive and highly sensitive isolation and characterization of circulating tumor cells (CTCs) from peripheral blood at single-cell resolution recapitulate MM in the bone marrow. We demonstrate that CTCs provide the same genetic information as bone marrow MM cells and even reveal mutations with greater sensitivity than bone marrow biopsies in some cases. Single CTC RNA sequencing enables classification of MM and quantitative assessment of genes that are relevant for prognosis. We propose that the genomic characterization of CTCs should be included in clinical trials to follow the emergence of resistant subclones after MM therapy.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Year:  2016        PMID: 27807282      PMCID: PMC5426804          DOI: 10.1126/scitranslmed.aac7037

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  47 in total

1.  Comparative gene marker selection suite.

Authors:  Joshua Gould; Gad Getz; Stefano Monti; Michael Reich; Jill P Mesirov
Journal:  Bioinformatics       Date:  2006-05-18       Impact factor: 6.937

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Authors:  J P Sharman; J Chmielecki; D Morosini; G A Palmer; J S Ross; P J Stephens; J Stafl; V A Miller; S M Ali
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-11

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  Targeting the BRAF V600E mutation in multiple myeloma.

Authors:  Mindaugas Andrulis; Nicola Lehners; David Capper; Roland Penzel; Christoph Heining; Jennifer Huellein; Thorsten Zenz; Andreas von Deimling; Peter Schirmacher; Anthony D Ho; Hartmut Goldschmidt; Kai Neben; Marc S Raab
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

7.  Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells.

Authors:  F Latron; M Jotterand-Bellomo; A Maffei; L Scarpellino; M Bernard; J L Strominger; R S Accolla
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

Review 8.  Targeting B-cell maturation antigen in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotherapy       Date:  2015-09-15       Impact factor: 4.196

9.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.

Authors:  Bo Li; Colin N Dewey
Journal:  BMC Bioinformatics       Date:  2011-08-04       Impact factor: 3.307

10.  Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.

Authors:  Jens G Lohr; Viktor A Adalsteinsson; Kristian Cibulskis; Atish D Choudhury; Mara Rosenberg; Peter Cruz-Gordillo; Joshua M Francis; Cheng-Zhong Zhang; Alex K Shalek; Rahul Satija; John J Trombetta; Diana Lu; Naren Tallapragada; Narmin Tahirova; Sora Kim; Brendan Blumenstiel; Carrie Sougnez; Alarice Lowe; Bang Wong; Daniel Auclair; Eliezer M Van Allen; Mari Nakabayashi; Rosina T Lis; Gwo-Shu M Lee; Tiantian Li; Matthew S Chabot; Amy Ly; Mary-Ellen Taplin; Thomas E Clancy; Massimo Loda; Aviv Regev; Matthew Meyerson; William C Hahn; Philip W Kantoff; Todd R Golub; Gad Getz; Jesse S Boehm; J Christopher Love
Journal:  Nat Biotechnol       Date:  2014-04-20       Impact factor: 54.908

View more
  59 in total

1.  Single Cell Genomics for Tumor Heterogeneity.

Authors:  Hae-Ock Lee; Woong-Yang Park
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population.

Authors:  Dean Bryant; Will Tapper; Nicola J Weston-Bell; Arnold Bolomsky; Li Song; Shengtao Xu; Andrew R Collins; Niklas Zojer; Surinder Singh Sahota
Journal:  Blood       Date:  2018-05-18       Impact factor: 22.113

Review 3.  Tracking myeloma tumor DNA in peripheral blood.

Authors:  Johannes M Waldschmidt; Tushara Vijaykumar; Birgit Knoechel; Jens G Lohr
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-14       Impact factor: 3.020

4.  Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.

Authors:  Mailee Huynh; Chorom Pak; Stephanie Markovina; Natalie S Callander; Kenneth S Chng; Shelly M Wuerzberger-Davis; Debayan D Bakshi; John A Kink; Peiman Hematti; Chelsea Hope; Fotis Asimakopoulos; Lixin Rui; Shigeki Miyamoto
Journal:  J Biol Chem       Date:  2017-12-26       Impact factor: 5.157

Review 5.  High-dimension single-cell analysis applied to cancer.

Authors:  Lili Wang; Kenneth J Livak; Catherine J Wu
Journal:  Mol Aspects Med       Date:  2017-08-30

Review 6.  Targeted therapies for renal cell carcinoma.

Authors:  Edwin M Posadas; Suwicha Limvorasak; Robert A Figlin
Journal:  Nat Rev Nephrol       Date:  2017-07-10       Impact factor: 28.314

7.  Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

Authors:  M A Baertsch; R Lutz; M S Raab; N Weinhold; H Goldschmidt
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-12       Impact factor: 4.553

Review 8.  Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.

Authors:  Johannes M Waldschmidt; Praveen Anand; Birgit Knoechel; Jens G Lohr
Journal:  Semin Hematol       Date:  2018-03-01       Impact factor: 3.851

Review 9.  Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.

Authors:  Vincent L Chen; Dabo Xu; Max S Wicha; Anna S Lok; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-11       Impact factor: 11.382

Review 10.  Targeting minimal residual disease: a path to cure?

Authors:  Marlise R Luskin; Mark A Murakami; Scott R Manalis; David M Weinstock
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.